Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
Total Operating Expenses (Q4 2024): $39.9 million, down 62% from Q4 2023. Research and Development Expenses (Q4 2024): $22.9 million, compared to $44.9 million in Q4 2023. Selling, General, and Administrative Expenses (Q4 2024): $17.1 million, compared to $52.2 million in Q4 2023. Cash Used in Operating Expenses (Q4 2024): Approximately $27 million. Cash Used for Discontinuation Obligations: Approximately $31 million for previously recognized items related to the discontinuation of Relibrio Albriosa. Remaining Discontinuation Obligations: Approximately $7.8 million expected to be paid through 2025. Warning! GuruFocus has detected 5 Warning Signs with AMLX. Release Date: March 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Amylyx Pharmaceuticals Inc ( NASDAQ:AMLX ) has initiated a pivotal study of Avexotide for post-bariatric hypoglycemia, with topline results expected in the first half o
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA TrialBusiness Wire
- HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
- Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLXBusiness Wire
- Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLXBusiness Wire
AMLX
Earnings
- 11/6/25 - Beat
AMLX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/17/25 - Form SCHEDULE
- AMLX's page on the SEC website